Foghorn Therapeutics Inc. 8-K Report: Key Updates on January 13, 2025

Based on the provided section of the financial report, here are the key extracted details:

Entity Information:

Company Name: Foghorn Therapeutics Inc.
CIK: 0001822462
IRS Employer Identification Number: 47-5271393
Address: 500 Technology Square, Ste 700, Cambridge, MA 02139
Phone Number: 617-586-3100
Stock Exchange: NASDAQ
Ticker Symbol: FHTX

Filing Information:

Filing Type: 8-K (a current report used to disclose significant events)
Filing Date: January 13, 2025
Period Covered: The report pertains to a single day, January 13, 2025.

Stock Information:

Common Stock Par Value: $0.0001 per share

Context:

The document is part of an XBRL (eXtensible Business Reporting Language) filing, which is a standardized format used for electronic submission of financial statements to the SEC.

Insights:

The 8-K filing suggests that there may be significant or material events related to Foghorn Therapeutics Inc. that warranted immediate disclosure on January 13, 2025.
Given the nature of the 8-K filing, investors and stakeholders should monitor the report closely for information regarding corporate actions, financial results, or other significant developments that may impact the company's stock performance and operations.
The low par value of the common stock might indicate a growth-oriented company that may engage in stock splits or other capital structure changes in the future.

For a comprehensive analysis, additional context on the content of the 8-K filing itself would be necessary to understand the specific events or changes being reported.